Is Sunshine Biopharma Stock a Good Investment?
Sunshine Biopharma Investment Advice | SBFM |
- Examine Sunshine Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sunshine Biopharma's leadership team and their track record. Good management can help Sunshine Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Sunshine Biopharma's business and its evolving consumer preferences.
- Compare Sunshine Biopharma's performance and market position to its competitors. Analyze how Sunshine Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Sunshine Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sunshine Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sunshine Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sunshine Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Sunshine Biopharma Stock
Researching Sunshine Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sunshine Biopharma recorded a loss per share of 127.9. The entity last dividend was issued on the 6th of April 2020. The firm had 1:20 split on the 8th of August 2024.
To determine if Sunshine Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sunshine Biopharma's research are outlined below:
| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Camille Sebaaly of 129468927 shares of Sunshine Biopharma subject to Rule 16b-3 |
Sunshine Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sunshine Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sunshine Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Sunshine Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sunshine Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2023-08-14 | 2023-06-30 | -0.08 | -0.02 | 0.06 | 75 | ||
2024-05-20 | 2024-03-31 | -1.04 | -2.0 | -0.96 | 92 | ||
2024-03-28 | 2023-12-31 | -3 | -5.0 | -2.0 | 66 | ||
2024-08-16 | 2024-06-30 | -7.4 | -9.94 | -2.54 | 34 | ||
2024-11-11 | 2024-09-30 | 9 | -0.94 | -9.94 | 110 |
Know Sunshine Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sunshine Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sunshine Biopharma backward and forwards among themselves. Sunshine Biopharma's institutional investor refers to the entity that pools money to purchase Sunshine Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Main Street Group Ltd | 2024-09-30 | 0.0 | Nordwand Advisors Llc | 2024-12-31 | 0.0 | Connective Capital Management Llc | 2024-12-31 | 11.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.6 K | Ubs Group Ag | 2024-12-31 | 868 | Sbi Securities Co Ltd | 2024-12-31 | 709 | Bank Of America Corp | 2024-12-31 | 5.0 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 4.0 | Td Waterhouse Canada Inc | 2024-12-31 | 1.0 | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 1.0 | Rise Advisors, Llc | 2024-12-31 | 1.0 |
Sunshine Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.18 M.Market Cap |
|
Sunshine Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.24) | (0.23) |
Determining Sunshine Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Sunshine Biopharma is a good buy. For example, gross profit margin measures Sunshine Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sunshine Biopharma's profitability and make more informed investment decisions.
Evaluate Sunshine Biopharma's management efficiency
Sunshine Biopharma has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1798) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to -0.16. In addition to that, Return On Capital Employed is likely to grow to -0.19. At this time, Sunshine Biopharma's Intangible Assets are very stable compared to the past year. As of the 24th of March 2025, Fixed Asset Turnover is likely to grow to 22.48, though Return On Tangible Assets are likely to grow to (0.16).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.6 K | 1.6 K | |
| Tangible Book Value Per Share | 1.5 K | 1.5 K | |
| Enterprise Value Over EBITDA | 2.12 | 2.23 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 2.12 | 2.23 | |
| Price Fair Value | 0.36 | 0.34 |
The strategic decisions made by Sunshine Biopharma management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Beta (1.48) |
Basic technical analysis of Sunshine Stock
As of the 24th of March, Sunshine Biopharma has the Variance of 19.46, coefficient of variation of (2,361), and Risk Adjusted Performance of (0.03). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sunshine Biopharma, as well as the relationship between them. Please validate Sunshine Biopharma market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Sunshine Biopharma is priced more or less accurately, providing market reflects its prevalent price of 2.1 per share. Please also confirm Sunshine Biopharma jensen alpha, which is currently at (0.07) to double-check the company can sustain itself at a future point.Sunshine Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sunshine Biopharma's Outstanding Corporate Bonds
Sunshine Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sunshine Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sunshine bonds can be classified according to their maturity, which is the date when Sunshine Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Sunshine Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sunshine Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 3.15 | |||
| Coefficient Of Variation | (2,361) | |||
| Standard Deviation | 4.41 | |||
| Variance | 19.46 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.1382 | |||
| Treynor Ratio | (0.10) | |||
| Maximum Drawdown | 24.99 | |||
| Value At Risk | (7.36) | |||
| Potential Upside | 7.91 | |||
| Skewness | (0.14) | |||
| Kurtosis | 1.54 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 3.15 | |||
| Coefficient Of Variation | (2,361) | |||
| Standard Deviation | 4.41 | |||
| Variance | 19.46 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | 0.1382 | |||
| Treynor Ratio | (0.10) | |||
| Maximum Drawdown | 24.99 | |||
| Value At Risk | (7.36) | |||
| Potential Upside | 7.91 | |||
| Skewness | (0.14) | |||
| Kurtosis | 1.54 |
Consider Sunshine Biopharma's intraday indicators
Sunshine Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sunshine Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sunshine Biopharma Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 21st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of January 2025 Other Reports | ViewVerify |
Sunshine Stock media impact
Far too much social signal, news, headlines, and media speculation about Sunshine Biopharma that are available to investors today. That information is available publicly through Sunshine media outlets and privately through word of mouth or via Sunshine internal channels. However, regardless of the origin, that massive amount of Sunshine data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sunshine Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sunshine Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sunshine Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sunshine Biopharma alpha.
Sunshine Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sunshine Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sunshine Biopharma's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.